Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome.

Kuehn HS, Caminha I, Niemela JE, Rao VK, Davis J, Fleisher TA, Oliveira JB.

J Immunol. 2011 May 15;186(10):6035-43. doi: 10.4049/jimmunol.1100021. Epub 2011 Apr 13.

2.

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology.

Blood. 2011 Apr 21;117(16):4190-207. doi: 10.1182/blood-2010-08-302984. Epub 2011 Feb 16. Review.

3.

Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation.

Magerus-Chatinet A, Neven B, Stolzenberg MC, Daussy C, Arkwright PD, Lanzarotti N, Schaffner C, Cluet-Dennetiere S, Haerynck F, Michel G, Bole-Feysot C, Zarhrate M, Radford-Weiss I, Romana SP, Picard C, Fischer A, Rieux-Laucat F.

J Clin Invest. 2011 Jan;121(1):106-12. doi: 10.1172/JCI43752. Epub 2010 Dec 22.

4.

Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis.

Niemela JE, Lu L, Fleisher TA, Davis J, Caminha I, Natter M, Beer LA, Dowdell KC, Pittaluga S, Raffeld M, Rao VK, Oliveira JB.

Blood. 2011 Mar 10;117(10):2883-6. doi: 10.1182/blood-2010-07-295501. Epub 2010 Nov 15.

5.

Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation.

Takagi M, Shinoda K, Piao J, Mitsuiki N, Takagi M, Matsuda K, Muramatsu H, Doisaki S, Nagasawa M, Morio T, Kasahara Y, Koike K, Kojima S, Takao A, Mizutani S.

Blood. 2011 Mar 10;117(10):2887-90. doi: 10.1182/blood-2010-08-301515. Epub 2010 Nov 9.

6.

Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency.

Rensing-Ehl A, Warnatz K, Fuchs S, Schlesier M, Salzer U, Draeger R, Bondzio I, Joos Y, Janda A, Gomes M, Abinun M, Hambleton S, Cant A, Shackley F, Flood T, Waruiru C, Beutel K, Siepermann K, Dueckers G, Niehues T, Wiesel T, Schuster V, Seidel MG, Minkov M, Sirkiä K, Kopp MV, Korhonen M, Schwarz K, Ehl S, Speckmann C.

Clin Immunol. 2010 Dec;137(3):357-65. doi: 10.1016/j.clim.2010.08.008. Epub 2010 Sep 15.

PMID:
20832369
7.

Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop.

Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, Rieux-Laucat F, Siegel RM, Su HC, Teachey DT, Rao VK.

Blood. 2010 Oct 7;116(14):e35-40. doi: 10.1182/blood-2010-04-280347. Epub 2010 Jun 10.

8.

Scleritis and multiple systemic autoimmune manifestations in chronic natural killer cell lymphocytosis associated with elevated TCRalpha/beta+CD3+CD4-CD8- double-negative T cells.

Yeh S, Li Z, Sen HN, Lim WK, Gill F, Perkins K, Rao VK, Nussenblatt RB.

Br J Ophthalmol. 2010 Jun;94(6):748-52. doi: 10.1136/bjo.2009.171264.

9.

Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.

Dowdell KC, Niemela JE, Price S, Davis J, Hornung RL, Oliveira JB, Puck JM, Jaffe ES, Pittaluga S, Cohen JI, Fleisher TA, Rao VK.

Blood. 2010 Jun 24;115(25):5164-9. doi: 10.1182/blood-2010-01-263145. Epub 2010 Apr 1.

10.

Autoimmune Lymphoproliferative Syndrome.

Bleesing JJH, Johnson J, Zhang K.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016.
2006 Sep 14 [updated 2014 Sep 11].

11.

Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome.

Caminha I, Fleisher TA, Hornung RL, Dale JK, Niemela JE, Price S, Davis J, Perkins K, Dowdell KC, Brown MR, Rao VK, Oliveira JB.

J Allergy Clin Immunol. 2010 Apr;125(4):946-949.e6. doi: 10.1016/j.jaci.2009.12.983. Epub 2010 Mar 15. No abstract available.

12.

Development of disseminated histiocytic sarcoma in a patient with autoimmune lymphoproliferative syndrome and associated Rosai-Dorfman disease.

Venkataraman G, McClain KL, Pittaluga S, Rao VK, Jaffe ES.

Am J Surg Pathol. 2010 Apr;34(4):589-94. doi: 10.1097/PAS.0b013e3181d5ddf8.

13.

Childhood polyarteritis nodosa in autoimmune lymphoproliferative syndrome.

Naumann-Bartsch N, Stachel D, Morhart P, Staatz G, Jüngert J, Schwarz K, Holter W.

Pediatrics. 2010 Jan;125(1):e169-73. doi: 10.1542/peds.2009-1999. Epub 2009 Dec 21.

PMID:
20026502
14.

Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study.

Thomsen RW, Schoonen WM, Farkas DK, Riis A, Jacobsen J, Fryzek JP, Sørensen HT.

Ann Intern Med. 2009 Oct 20;151(8):546-55.

PMID:
19841456
15.

Vascular complications after splenectomy for hematologic disorders.

Crary SE, Buchanan GR.

Blood. 2009 Oct 1;114(14):2861-8. doi: 10.1182/blood-2009-04-210112. Epub 2009 Jul 27. Review.

16.

Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS).

Dowdell KC, Pesnicak L, Hoffmann V, Steadman K, Remaley AT, Cohen JI, Straus SE, Rao VK.

Exp Hematol. 2009 Apr;37(4):487-94. doi: 10.1016/j.exphem.2008.12.002. Epub 2009 Feb 12.

17.

Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS).

Rao VK, Price S, Perkins K, Aldridge P, Tretler J, Davis J, Dale JK, Gill F, Hartman KR, Stork LC, Gnarra DJ, Krishnamurti L, Newburger PE, Puck J, Fleisher T.

Pediatr Blood Cancer. 2009 Jul;52(7):847-52. doi: 10.1002/pbc.21965.

18.

Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome.

Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, Manno C, Rappaport E, Schwabe D, Sheen C, Sullivan KE, Zhuang H, Wechsler DS, Grupp SA.

Br J Haematol. 2009 Apr;145(1):101-6. doi: 10.1111/j.1365-2141.2009.07595.x. Epub 2009 Feb 4.

19.

Immune thrombocytopenic purpura: the treatment paradigm.

Stasi R.

Eur J Haematol Suppl. 2009 Mar;(71):13-9. doi: 10.1111/j.1600-0609.2008.01208.x. Review.

PMID:
19200303
20.

FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function.

Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, Neven B, Schaffner C, Ducrot N, Arkwright PD, Bader-Meunier B, Barbot J, Blanche S, Casanova JL, Debré M, Ferster A, Fieschi C, Florkin B, Galambrun C, Hermine O, Lambotte O, Solary E, Thomas C, Le Deist F, Picard C, Fischer A, Rieux-Laucat F.

Blood. 2009 Mar 26;113(13):3027-30. doi: 10.1182/blood-2008-09-179630. Epub 2009 Jan 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk